People taking blood-thinning medicines such as Warfarin need regular blood tests to check how well the medicines are working. The most common test is the PT/INR test (Prothrombin Time/International Normalized Ratio). People taking Warfarin must have the effect of drug monitored regularly, as often as once a week.

 

At present, all PT/INR testing, whether Point-of-Care or self-testing, requires an expensive reader device in addition to the actual test strips. Even though medical authorities are calling for increased self-testing, in 2011 only 13% of coagulation testing performed worldwide was self-testing.

 

The Self-Testing Market Opportunity:

• 20 million existing Warfarin users in the United States.

–Estimated 2 million new users each year

• Recommended weekly testing.

–Equates to a potential 1 billion tests each year.

 

Epinex SimplySure PT-INR Advantage Over the Competition:

• SimplySure PT-INR does not require complex and costly instrumentation for testing.

• All competition requires upfront instrument/device cost >$900.

• Simplicity and cost effectiveness of SimplySure PT-INR enables easy physician office or self-testing without need for additional infrastructure or patient assistance.

• Disposable test design facilitates INR monitoring at any time any place.